These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 19368119)

  • 1. In vivo studies on the availability and toxicity of antisense oligonucleotides in bladder cancer.
    Blietz CE; Thode B; Hauses M; Pries R; Meyer AJ; Doehn C; Jocham D; Kausch I
    In Vivo; 2009; 23(1):13-9. PubMed ID: 19368119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 inhibit the growth of non-muscle-invasive bladder cancer.
    Hadaschik BA; Jackson J; Fazli L; Zoubeidi A; Burt HM; Gleave ME; So AI
    BJU Int; 2008 Aug; 102(5):610-6. PubMed ID: 18384625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo.
    Konety BR; Lavelle JP; Pirtskalaishvili G; Dhir R; Meyers SA; Nguyen TS; Hershberger P; Shurin MR; Johnson CS; Trump DL; Zeidel ML; Getzenberg RH
    J Urol; 2001 Jan; 165(1):253-8. PubMed ID: 11125420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
    Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
    BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ki-67-directed antisense therapy in an orthotopic renal cell carcinoma model.
    Kausch I; Jiang H; Brocks C; Bruderek K; Krüger S; Sczakiel G; Jocham D; Böhle A
    Eur Urol; 2004 Jul; 46(1):118-24; discussion 124-5. PubMed ID: 15183557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel and cisplatin as intravesical agents against non-muscle-invasive bladder cancer.
    Hadaschik BA; ter Borg MG; Jackson J; Sowery RD; So AI; Burt HM; Gleave ME
    BJU Int; 2008 Jun; 101(11):1347-55. PubMed ID: 18384637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin.
    Hadaschik BA; Adomat H; Fazli L; Fradet Y; Andersen RJ; Gleave ME; So AI
    Clin Cancer Res; 2008 Mar; 14(5):1510-8. PubMed ID: 18316576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine.
    Song D; Wientjes MG; Gan Y; Au JL
    Clin Cancer Res; 1997 Jun; 3(6):901-9. PubMed ID: 9815765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model.
    Xiao Z; Mak A; Koch K; Moore RB
    BJU Int; 2013 Jul; 112(2):E201-10. PubMed ID: 23356235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microscopic quantification of hypercin fluorescence in an orthotopic rat bladder tumor model after intravesical instillation.
    Kamuhabwa AA; Roskams T; Baert L; De Witte PA
    Int J Oncol; 2003 Apr; 22(4):933-7. PubMed ID: 12632090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin.
    Kawano H; Komaba S; Yamasaki T; Maeda M; Kimura Y; Maeda A; Kaneda Y
    Cancer Chemother Pharmacol; 2008 May; 61(6):973-8. PubMed ID: 17653716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer.
    Rosato A; Banzato A; De Luca G; Renier D; Bettella F; Pagano C; Esposito G; Zanovello P; Bassi P
    Urol Oncol; 2006; 24(3):207-15. PubMed ID: 16678050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bladder wall penetration of intravesical mitomycin C in dogs.
    Wientjes MG; Dalton JT; Badalament RA; Drago JR; Au JL
    Cancer Res; 1991 Aug; 51(16):4347-54. PubMed ID: 1907883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ki-67 antisense therapy in murine renal cell carcinoma models].
    Kausch I; Jiang H; Brocks C; Albers A; Krüger S; Sczakiel G; Jocham D
    Aktuelle Urol; 2005 Apr; 36(2):142-8. PubMed ID: 15902575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine.
    Gao X; Au JL; Badalament RA; Wientjes MG
    Clin Cancer Res; 1998 Jan; 4(1):139-43. PubMed ID: 9516962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic vesicular stomatitis viruses are potent agents for intravesical treatment of high-risk bladder cancer.
    Hadaschik BA; Zhang K; So AI; Fazli L; Jia W; Bell JC; Gleave ME; Rennie PS
    Cancer Res; 2008 Jun; 68(12):4506-10. PubMed ID: 18559493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboxyamido-triazole (CAI) reverses the balance between proliferation and apoptosis in a rat bladder cancer model.
    Perabo FG; Demant AW; Wirger A; Schmidt DH; Sitia M; Wardelmann E; Müller SC; Kohn EC
    Anticancer Res; 2005; 25(2A):725-9. PubMed ID: 15868902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EDTA-induced urothelial cell shedding for the treatment of superficial bladder cancer in the mouse.
    Nativ O; Dalal E; Hidas G; Aronson M
    Int J Urol; 2006 Oct; 13(10):1344-6. PubMed ID: 17010016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.
    Ord JJ; Streeter E; Jones A; Le Monnier K; Cranston D; Crew J; Joel SP; Rogers MA; Banks RE; Roberts IS; Harris AL
    Br J Cancer; 2005 Jun; 92(12):2140-7. PubMed ID: 15928663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.